Sp2/mIL-6 (ATCC® CRL-2016™)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: Hybridoma: B lymphocyte

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type Hybridoma: B lymphocyte
Product Format frozen
Morphology Lymphoblast-like
Culture Properties Suspension
Biosafety Level 1
Applications

It is a mouse fusion cell line derived from Sp2/0 cells that had been transfected with high-titer L6PNL recombinant retrovirus carrying a mouse interleukin-6 (IL-6) cDNA under the transcriptional control of the viral LTR and the neo gene encoding bacterial neomycin phosphotransferase (G418 resistance).

Sp2/IL-6 cells secrete IL-6 and are an improved myeloma fusion parent in terms of both the relative number of viable B cell hybridomas producing immunoglobulin and the proportion of hybridomas producing antigen-specific monoclonal antibodies.



Sp2/IL-6 cells secrete IL-6 and are an improved myeloma fusion parent in terms of both the relative number of viable B cell hybridomas producing immunoglobulin and the proportion of hybridomas producing antigen-specific monoclonal antibodies.
Sp2/mIL-6 cells have stably incorporated in their genome approximately six copies of the retroviral vector L6PNL and constitutively secrete large quantities of mouse IL-6 (10,000 units/ml).
Derivation
The Sp2/mIL-6 line was established by R. Hawley and T. Hawley of the Sunnybrook Health Centre, Toronto, Canada. It is a mouse fusion cell line derived from Sp2/0 cells that had been transfected with high-titer L6PNL recombinant retrovirus carrying a mouse interleukin-6 (IL-6) cDNA under the transcriptional control of the viral LTR and the neo gene encoding bacterial neomycin phosphotransferase (G418 resistance). 
Antigen Expression Antigen expression: H-2, d haplotype; Mus musculus, expressed
Genes Expressed
mouse interleukin 6 (interleukin-6, IL-6),H-2, d haplotype; Mus musculus, expressed
Complete Growth Medium The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water. To make the complete growth medium, add the following components to the base medium:
  • fetal bovine serum to a final concentration of 10%
  • 1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere
  • 0.05 mM 2-Mercaptoethanol

Subculturing
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start new cultures at 2 X 10(5) cells/ml and subculture before the cell density reaches 2 X 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 4 days (depending on cell density)
Culture Conditions
Temperature: 37.0°C
Name of Depositor JF Harris
References

Harris JF, et al. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J. Immunol. Methods 148: 199-207, 1992. PubMed: 1373425

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
MSDS
MSDS
Restrictions Note: These cells are distributed for research purposes only. Dr. Harris releases the line subject to the following: 1.) The Sp2/mIl-6 cells or any cells derived from SP2/mIL-6 or any antibody derived from it must not be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. 2.) Any proposed commercial use of these cells should first be negotiated with the London Regional Cancer Centre, 790 Commissioners Road, East, London, Ontario. N6A 4L6 Canada. 3.) In all papers reporting any use of these or derived clones a direct reference will be made to the original publication (J. Immunol. Methods 148: 199-207, 1992).
References

Harris JF, et al. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J. Immunol. Methods 148: 199-207, 1992. PubMed: 1373425